Actively Recruiting
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
Led by Saglik Bilimleri Universitesi · Updated on 2025-12-08
54
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
CONDITIONS
Official Title
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)
- Signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)
- Intravitreal injection already clinically indicated
You will not qualify if you...
- Patients younger than 45 years or older than 90 years
- History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months
- Presence of uveitis
- Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)
- Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)
- Presence of hereditary retinal dystrophies
- Presence of optic atrophy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prof. Dr. Cemil Taşcıoğlu City Hospital
Istanbul, şişli, Turkey (Türkiye), 34384
Actively Recruiting
Research Team
S
Sinan Kalpakoğlu, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here